Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,948,888
  • Shares Outstanding, K 725,910
  • Annual Sales, $ 22,991 M
  • Annual Income, $ 7,722 M
  • 36-Month Beta 1.36
  • Price/Sales 5.58
  • Price/Cash Flow 12.08
  • Price/Book 3.98

Price Performance

See More
Period Period Low Period High Performance
1-Month
168.15 +5.57%
on 11/20/17
180.74 -1.79%
on 12/04/17
+6.01 (+3.50%)
since 11/13/17
3-Month
168.15 +5.57%
on 11/20/17
191.10 -7.11%
on 09/14/17
-12.19 (-6.43%)
since 09/13/17
52-Week
145.12 +22.32%
on 12/22/16
191.10 -7.11%
on 09/14/17
+29.14 (+19.64%)
since 12/13/16

Most Recent Stories

More News
Roche/AbbVie Report Positive Phase III Results on Venclexta

Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory...

NVS : 84.63 (+0.20%)
ABBV : 98.12 (+1.89%)
RHHBY : 30.4400 (+0.33%)
AMGN : 177.10 (+0.48%)
Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the first quarter of 2018. The dividend will be paid on March 8, 2018, to all stockholders of record...

AMGN : 177.10 (+0.48%)
Roche Reports Positive Data from Tecentriq Combination Study

Roche reported positive data from a combination study of Tecentriq and Avastin in metastatic renal cell carcinoma patients.

AGN : 169.71 (-1.26%)
RHHBY : 30.4400 (+0.33%)
AMGN : 177.10 (+0.48%)
KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial

Amgen (NASDAQ: AMGN) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of OS,...

AMGN : 177.10 (+0.48%)
3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise

With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.

BLUE : 181.75 (-4.82%)
JNJ : 142.52 (-0.06%)
INCY : 98.75 (+3.51%)
GILD : 76.65 (+0.74%)
AMGN : 177.10 (+0.48%)
JUNO : 46.36 (+1.33%)
SNY : 43.90 (-0.14%)
Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires

Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the Southern California wildfires. Of this commitment, $200,000 will be directed to the United Way...

AMGN : 177.10 (+0.48%)
Sanofi Begins Combo Studies on Multiple Myeloma Candidate

Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.

CELG : 107.75 (-1.18%)
JNJ : 142.52 (-0.06%)
AMGN : 177.10 (+0.48%)
SNY : 43.90 (-0.14%)
New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers

Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from 33 abstracts, including six oral presentations, evaluating approved medicines and investigational immuno-oncology agents from...

AMGN : 177.10 (+0.48%)
Erythropoietin Drugs Market Value to Reach US$19,379.2 Million by the end of 2025: Transparency Market Research

Transparency Market Research states that the key players operating in the global erythropoietin drugs market are focusing on product development. The intensifying competition is expected to coax players...

MRK : 56.80 (-0.47%)
NVS : 84.63 (+0.20%)
AMGN : 177.10 (+0.48%)
Amgen To Webcast Investor Call At ASH 2017

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition on Saturday, Dec. 9, 2017, at 11:30 a.m. ET. David...

AMGN : 177.10 (+0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 178.65
1st Resistance Point 177.46
Last Price 177.10
1st Support Level 174.60
2nd Support Level 172.93

See More

52-Week High 191.10
Last Price 177.10
Fibonacci 61.8% 173.54
Fibonacci 50% 168.11
Fibonacci 38.2% 162.68
52-Week Low 145.12

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.